Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Serlect NDA withdrawn; Lundbeck U.K. cohort study focusing on arrhythmias.

Executive Summary

ABBOTT SERLECT STUDY PLANS UNDECIDED AFTER NDA WITHDRAWAL Jan. 13, the company said. Abbott has said that it is conducting clinical trials examining the antipsychotic Serlect (sertindole) in patients failing risperidone (Janssen's Risperdal) and an open-label extension of trial M94-222. A study in Alzheimer's disease patients was planned in 1996. The Danish firm H. Lundbeck, which licenses sertindole to Abbott for the U.S., Canada, and Latin American territories, continues to market the drug as Serdolect in 12 European countries.

You may also be interested in...

Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup

Lundbeck CEO-elect Claus Braestrup will oversee the company's renewed attempt to launch the antipsychotic Serlect (sertindole) in the U.S. when he assumes leadership of the Danish company in November

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts